NDAINTRAVENOUSPOWDERPriority Review
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Clinical Trials (5)
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Started May 2026
16 enrolled
Small Cell Lung Cancer ( SCLC )Transformed Small Cell Lung Cancer
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Started Apr 2026
50 enrolled
Extensive-stage Small-cell Lung Cancer
Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas
Started Oct 2024
0Locally Advanced Soft Tissue Sarcoma
Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
Started Oct 2023
0Small Cell Lung CancerPlatinum-Sensitive Lung Small Cell CarcinomaExtensive-stage Small-cell Lung Cancer
Lurbinectedin in FET-Fused Tumors
Started Jul 2023
63 enrolled
Ewing SarcomaDesmoplastic Small Round Cell TumorPediatric Cancer+1 more
Loss of Exclusivity
LOE Date
May 29, 2040
173 months away
Patent Expiry
May 29, 2040
Exclusivity Expiry
Oct 2, 2028